INTRODUCTION
Colorectal cancer is a disease with a high incidence and mortality rate, and has been increasing in prevalence worldwide (1) . Therefore, various prevention strategies have been investigated. Primary prevention attempts to prevent the occurrence of colorectal cancer by lifestyle modification, and secondary prevention aims to arrest the progression of colorectal cancer through early diagnosis and treatment. In addition to these, recently, chemoprevention, the use of oral drugs to prevent cancer, has attracted much attention. Many compounds have been tested to assess their inhibition of colorectal carcinogenesis in animal models, and some of them have been proceeded to clinical trials for chemoprevention.
Recent progress in the molecular analysis of colorectal carcinogenesis has revealed many candidate molecules for chemopreventive agents. In this review, we summarize new findings regarding experimental data and clinical trials for the chemoprevention of colorectal cancer. the most widely used as a model of sporadic colorectal carcinogenesis, and is reportedly very similar to human colorectal cancer in terms of the clinical symptoms, clinical course, and pathological findings (2) . The other one is the genetic model harboring gene mutations such as APC, p53, etc. The Min mouse and Apc delta716 knockout mouse, both of which have APC mutations, are also used worldwide (3, 4) .
In 1987, Bird reported a tiny lesion consisting of large, thick crypts in a methylene blue-stained specimen of the colon from mice treated with azoxymethane, and suggested to be a precursor lesion of colorectal cancer in the animal model (5) . Then, abundant evidence was reported to support that aberrant crypt foci (ACF) are a precursor lesion of colorectal cancer. Thus, ACF are often used as a target lesion to test chemopreventive effects in animal models of colorectal carcinogenesis.
CHEMOPREVENTIVE AGENTS AND TAR-GET MOLECULES
Recent progress in the molecular analysis of colorectal cancer has made it possible to target a specific molecule for chemoprevention (6) . Many promising target molecules have been reported so far (Table 1 ). These can be mainly classified into 3 categories based on the mechanism : 1) signal transduction modulation, 2) epigenetic modulation, and 3) anti-inflammatory modulation.
1) Signal transduction modulator
The signal transduction pathway has been searched for a long time as a target of chemotherapy and chemoprevention. EGF receptor inhibitors (Erlotinib, etc.), anti-EGF receptor antibody (Cetuximab), and anti-VEGF antibody (Bevacizumab) are well-known as therapeutic agents for cancer and commonly used worldwide (7) . Although these agents have not yet been applied to chemoprevention, they themselves or their analogues may be put to practical use as chemopreventive agents of colorectal cancer in the future. Since mutations of K-ras and p53 are frequently observed in colorectal cancer, their oncogenic pathway is a possible target. Anti-ras agents such as Tipifarnib and perilyl alcohol, and anti -p53 agents such as CP31398 have been reported to inhibit colorectal carcinogenesis in animal models (8) . Other signal transduction modulators targeting Bcl-2, ODC, GST-pi, etc., have also been examined for their chemopreventive effect on colorectal cancer.
2) Epigenetic modulation
It is well known that peroxisome proliferatoractivated receptor (PPAR)-γ and -δ play a role in the 
3) Anti-inflammatory modulation
Cyclooxygenase-2 (COX-2) is reportedly overexpressed in colorectal adenoma and cancer of rodents and humans. It is also reported that COX-2 promotes the cell growth and inhibits apoptosis of colorectal epithelia. When an Apc delta716 knockout mouse, a model of human familial adenomatous polyposis, was crossed with a COX-2 knockout mouse, the number and size of intestinal polyps were markedly reduced (10) . Moreover, there are many studies showing that selective COX-2 inhibitors suppressed colorectal adenoma and cancer. Thus, the efficacy of targeting the COX-2 molecule for chemoprevention was theoretically confirmed in animal models. There are also many other antiinflammatory agents including EP1-4 and NF-κB currently under investigation.
CLINICAL TRIAL FOR CHEMOPREVEN-TION
Representative human chemopreventive trials are shown in Table 2 . They are mainly classified into 3 categories according to the target lesion. The first one is a trial that targets a pre-existing polyp. Giardiello, et al. reported that sulindac significantly suppressed the number and size of polyps in familial adenomatous polyposis patients in 1993 (11) . This study prompted investigators to conduct a trial to examine whether or not sulindac suppresses sporadic polyps. However, it did not significantly suppress the number or size of the polyps (12) . This trial revealed that a pre-existing polyp is not necessarily an appropriate target for chemoprevention; a large polyp close to a cancer may not be able to respond to chemopreventive agents. Thus, chemoprevention targeting the development of a new polyp in polypectomized patients was conducted thereafter. Several randomized trials showed that aspirin inhibited the development of polyps. Since COX-2 was shown to be a good target molecule for chemoprevention in animal experiments, as noted above, two large-scale randomized clinical trials using a selective COX-2 selective inhibitor (celecoxib) were performed. Arber, et al. reported that celecoxib (400 and 800 mg/ day) significantly reduced the new development of adenoma compared to a placebo group (13) . Bertagnolli, et al. also reported that celecoxib (400 and 800 mg/day) significantly reduced the development of adenoma in a different large-scale trial (14) . However, in these trials, severe cardiovascular events including myocardial infarction and stroke occurred in about 20% of cases. Therefore, it is considered that the COX-2 inhibitor is an effective agent for the prevention of colorectal cancer, but it cannot be recommended for chemoprevention because of potential cardiovascular events. The third one is a trial that targets the development of cancer. This kind of trial is theoretically ideal because it examines if each agent indeed suppresses the development of cancer itself. However, it takes more than 4 years, and prolongation of the trial sometimes causes severe side effects and poor compliance.
CHEMOPREVENTION TARGETING ACF
Since ACF are the earliest precursor lesions of colorectal cancer (15, 16) , they would be an appropriate target for chemoprevention (Fig. 1) . The advantages of using ACF as targets over a polyp and cancer are as follows : (1) short-term treatment for evaluation, (2) fewer complications caused by drugs, and (3) good compliance. Thus, we performed an open trial in which sulindac was administered for various periods to subjects positive for ACF. The results showed that the majority of ACF were eradicated after only a few months. Based on this, we next performed a randomized double-blind trial targeting ACF consisting of groups receiving sulindac, etodolac (a selective COX -2 inhibitor), or a placebo. The detailed results of this study will be clarified in the near future.
EPILOGUE
Many candidate agents for chemoprevention are currently being tested, and some of them have actually shown potential chemopreventive activity in human trials. Although the COX-2 inhibitor failed to be a major chemopreventive agent, other effective new agents will be identified in the near future.
